CONMED Q2 adj EPS $0.98 beats; cuts FY revenue & EPS guidance on supply chain delays

CONMED Corp

2024-Q2 EPS reported $1.59 revenue$644,371,000

Revenue $332.1M (+4.5% reported, +5.2% constant currency); GAAP EPS $0.96 vs $0.43; adj EPS $0.98 vs $0.83 (+18.1%).
Full-year revenue guidance lowered to $1.305-1.315B from $1.330-1.355B; adj EPS guidance cut to $3.95-4.02 from $4.25-4.35.
CEO cites unresolved supply chain challenges delaying commercial reacceleration, impacting second half outlook.
Orthopedic Surgery sales -0.9% YoY; General Surgery +8.9%; Domestic +6.1%, International +2.6% reported.
Adjusted EBITDA $64.6M (19.4% margin) vs $57.6M (18.1%) in Q2 2023.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.